Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented MCL.~* Must have received at least one prior therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤1.~* Adequate organ function as outlined in the protocol.~Exclusion Criteria:~* Major surgery, radiation therapy, or systemic therapy within 4 weeks of study enrollment.~* Prior radiation therapy to \>25% of the bone marrow (whole pelvis is 25%).~* Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PD-0332991 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).